Prosecution ends when the patent office decides your claims are allowable. But the transition from "application" to "granted patent" is not automatic -- it involves fees, formalities, and a series of decisions that shape the scope and duration of your rights. This chapter covers what happens at grant, what your patent actually protects, how long that protection lasts, and -- critically -- what a patent does not give you.
What Happens at Grant
The Issue Fee and Grant Formalities
At the USPTO, the sequence begins with a Notice of Allowance. You then have three months to pay the issue fee (currently $1,200 for large entities, $480 for small entities, $300 for micro entities). If you fail to pay within this window, the application goes abandoned -- though revival is possible with a petition and surcharge if the delay was unintentional.
At the EPO, the process is slightly different. After the examining division communicates its intention to grant, the applicant must approve the text of the patent, pay the grant and printing fees, and file any required translations -- all within four months. The patent is then published in the European Patent Bulletin, and that publication date marks the formal grant.
The pattern is universal across offices: allowance is not the same as grant. There is always a final administrative step before the patent takes legal effect.
Publication and Effective Date
Once formalities are complete, the patent office publishes the granted patent. At the USPTO, the patent issues on a Tuesday and the certificate states the patent number, issue date, inventor names, assignee, and any patent term adjustment. At the EPO, the granted patent is published as a B1 publication, replacing the earlier A1 application publication.
In the United States, enforceable rights begin on the issue date. Provisional rights under 35 U.S.C. 154(d) may entitle you to a reasonable royalty for infringement between the publication date and grant date, but only if the published claims are substantially identical to the granted claims and the infringer had actual notice.
At the EPO, the granted patent must be validated in each designated member state (national fees, sometimes translations) before rights take effect there. The nine-month opposition window begins from the grant publication date.
| Event | USPTO | EPO |
|---|---|---|
| Notice of allowance / Intent to grant | Notice of Allowance mailed | Communication under Rule 71(3) |
| Fee deadline | 3 months to pay issue fee | 4 months to approve text, pay fees, file translations |
| Publication | Published on issue date (Tuesday) | Published in European Patent Bulletin |
| Rights begin | Issue date (provisional rights from publication) | Grant publication date, subject to national validation |
| Post-grant challenge window | IPR: 9 months after grant; PGR: 9 months after grant | Opposition: 9 months from grant publication |
What Your Patent Protects
The Right to Exclude
A patent does not give you the right to make, use, or sell anything. It gives you the right to exclude others from making, using, offering for sale, selling, or importing the patented invention. The patent grant is a negative right -- it tells others what they cannot do without your permission. The scope of that exclusionary right is defined entirely by the claims.
Claim Scope and Infringement
Literal infringement occurs when an accused product or process includes every element recited in at least one patent claim. If a claim requires elements A, B, and C, and the accused product has all three, there is literal infringement -- regardless of any additional elements.
Infringement under the doctrine of equivalents occurs when an accused product does not literally satisfy every claim element but performs substantially the same function, in substantially the same way, to achieve substantially the same result. This doctrine prevents competitors from avoiding infringement through trivial variations.
Prosecution history estoppel limits equivalents. If you narrowed a claim during prosecution to overcome a prior art rejection, you may be unable to use the doctrine of equivalents to recapture the surrendered scope. Every amendment you made during prosecution shapes the scope of your granted patent. This is why continuation practice (covered in Chapter 11) is so important -- broader claims in a related application can cover territory that estoppel forecloses in the narrowed patent.
Territorial Scope
Patents are strictly territorial. A U.S. patent provides no protection in Europe, China, or anywhere else. A European patent validated in Germany and France provides no protection in Spain unless it was also validated there. If you need protection in multiple jurisdictions, you need patents in each one -- through direct national filing, regional systems (EPO, ARIPO, OAPI), or the PCT route (covered in Chapter 13).
Patent Marking
Marking patented products with the patent number serves two purposes: it puts the public on notice that the product is patented, and it preserves your ability to collect damages from infringers.
Marking Requirements by Jurisdiction
| Jurisdiction | Marking Requirement | Consequence of Not Marking |
|---|---|---|
| United States | Optional but strongly recommended; mark with "Patent" or "Pat." and the patent number | Cannot recover damages for infringement occurring before the infringer received actual notice (35 U.S.C. 287) |
| European Patent Convention | No marking requirement | Damages available from the date of grant (or earlier, depending on national law) regardless of marking |
| United Kingdom | Optional; "patented" or the patent number | May limit damages recovery for pre-notice infringement |
| China | Optional; mark with patent number and type | May affect damages calculation |
| Japan | "Encouraged" under Article 187; mark with patent number | No statutory penalty for failure to mark, but marking affects constructive notice arguments |
Virtual Patent Marking
Since 2011, U.S. law has permitted virtual patent marking under 35 U.S.C. 287(a). Instead of printing a patent number on every product, you can mark products with "Patent" or "Pat." followed by a URL that lists the applicable patents. The webpage must be freely accessible to the public and must associate specific products with specific patent numbers.
Virtual marking is now standard practice for companies with large portfolios, eliminating the need to update physical markings each time a new patent issues.
"Patent Pending" Status
Marking a product as "Patent Pending" has no legal effect -- it does not create enforceable rights or provide a basis for damages. Its purpose is to notify competitors that an application has been filed. False marking (claiming patent status when no application or patent exists) is unlawful under 35 U.S.C. 292.
Patent Term
The Standard Term
The modern standard for utility patents is 20 years measured from the earliest effective nonprovisional filing date. This is the rule in the United States (35 U.S.C. 154), under the European Patent Convention (Article 63), and in virtually every country that is a member of the WTO under the TRIPS Agreement.
Filing date, not grant date. The 20-year clock starts running from the day you file the nonprovisional application -- not from when the patent is granted. An application that spends six years in prosecution results in a patent with only 14 years of enforceable life (absent term extensions). This is why prosecution speed matters commercially.
Design patents follow different rules. In the United States, design patents filed on or after May 13, 2015 have a 15-year term from the grant date. Under the Hague Agreement, registered designs have an initial 5-year term, renewable up to 25 years in the EU.
Patent Term Adjustment (PTA) -- U.S. Only
Chapter 11 introduced PTA in the context of prosecution strategy. In brief, PTA compensates patent holders for delays caused by the USPTO during examination. It is calculated based on three categories of office delay (A, B, and C delays) and reduced by any period of applicant delay. PTA is stated on the face of the patent at issuance. It can add anywhere from zero to several hundred days -- or more in congested art units -- beyond the standard 20-year term.
Patent Term Extension for Regulatory Delays
Certain products -- pharmaceuticals, biologics, medical devices, agrochemicals -- require regulatory approval before they can be marketed, consuming years of patent term before the product reaches the market. Several legal mechanisms address this problem.
Hatch-Waxman Extensions (United States). Under 35 U.S.C. 156, the term of one patent covering a product subject to regulatory review by the FDA can be extended by up to five years to compensate for time lost during clinical testing and FDA review. The total effective patent life after the regulatory approval date cannot exceed 14 years. Only one patent per product can receive a Hatch-Waxman extension, and the application must be filed within 60 days of regulatory approval.
Supplementary Protection Certificates (European Union). SPCs extend protection for pharmaceutical and plant protection products beyond the standard 20-year patent term. An SPC can provide up to five additional years of protection (six years for pediatric medicines with an approved Pediatric Investigation Plan). The SPC takes effect the day after the base patent expires and covers only the product as authorized by the marketing authorization.
| Mechanism | Jurisdiction | Maximum Extension | Eligible Products | Key Limitation |
|---|---|---|---|---|
| Hatch-Waxman (35 U.S.C. 156) | United States | 5 years | Drugs, biologics, medical devices, food additives, color additives | Total post-approval patent life capped at 14 years; one patent per product |
| Supplementary Protection Certificate | European Union | 5 years (6 for pediatric) | Pharmaceuticals, plant protection products | Requires valid marketing authorization; one SPC per product per basic patent |
| Patent Term Restoration | Japan | 5 years | Pharmaceuticals, agrochemicals | Must apply within 3 months of regulatory approval |
| Data Protection / Regulatory Exclusivity | Multiple | Varies (5-12 years) | Biologics, orphan drugs, new chemical entities | Separate from patent term; prevents reliance on originator's regulatory data |
Illustrative patent term for a U.S. pharmaceutical patent: the base 20-year term, PTA for office delays, and Hatch-Waxman extension for regulatory delays. The enforceable commercial life begins only at regulatory approval.
Post-Grant Administrative Actions
Recording Assignments
Patent ownership can be transferred through an assignment at any time. At the USPTO, assignments should be recorded with the Assignment Center within three months. Failure to record within three months renders the assignment void against a subsequent purchaser for value without notice. Recordation is not required for validity between the parties, but it is essential for enforceability against third parties.
Certificates of Correction
If the granted patent contains errors, the patent owner can request a certificate of correction. Errors attributable to the patent office are corrected at no charge. Applicant errors of a minor or clerical nature can be corrected for a fee.
Reissue Patents
When a defect is too significant for a certificate of correction -- for example, claims broader or narrower than the inventor was entitled to -- the patent holder can apply for a reissue patent. A reissue replaces the original patent for the remainder of its unexpired term. No new matter can be added, and broadening reissues must be filed within two years of the original grant date at the USPTO.
Third-Party Rights and Limitations
Even after your patent is granted, certain third-party rights may limit your ability to exclude others from practicing the invention.
Prior User Rights
In the United States, 35 U.S.C. 273 provides a defense for anyone who commercially used the subject matter in good faith at least one year before the patent's effective filing date. Prior user rights are personal and non-transferable (except with the sale of the entire business that practiced the invention). Most EPC member states have similar provisions under national law: good-faith prior use before the priority date entitles the user to continue.
Research and Experimental Use
Most jurisdictions recognize some form of exemption for experimental or research use of patented inventions. The scope of this exemption varies dramatically:
- United States: The common-law experimental use exemption is extremely narrow -- it applies only to activities undertaken "for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry." Any commercial motivation, however indirect, defeats the defense. In practice, the U.S. experimental use exemption provides almost no protection for universities or companies engaged in research.
- Europe: Most EPC member states provide a broader statutory research exemption. Under national implementations, experiments carried out on a patented invention (to study it, test it, or develop improvements) are generally non-infringing, even if conducted for ultimately commercial purposes. The key distinction is between experiments on the invention (exempt) and experiments with the invention (potentially infringing).
- Japan: Article 69(1) of the Japan Patent Act provides an exemption for acts done for experimental or research purposes relating to the patented invention.
The Bolar Exemption (Regulatory Use)
The Bolar exemption permits use of a patented invention for activities reasonably related to obtaining regulatory approval -- most commonly, generic pharmaceutical companies conducting bioequivalence testing before the originator's patent expires. This exemption exists in the United States (35 U.S.C. 271(e)(1)), the EU, and most other major jurisdictions. Without it, generic entry would be delayed by years after patent expiry because the regulatory testing itself would constitute infringement.
Government use. In the United States, the federal government may use any patented invention without the patent owner's permission, but the owner is entitled to reasonable compensation under 28 U.S.C. 1498. Many other countries have similar sovereign use or compulsory licensing provisions.
What a Patent Does NOT Give You
A patent does not grant freedom to operate. Your patent gives you the right to stop others from practicing your invention. It does not guarantee that you can practice it yourself -- your product might incorporate technology covered by someone else's earlier patent. A freedom-to-operate analysis is a separate and essential exercise.
A patent does not guarantee commercial success. A patent protects a technical solution, not a market. Market demand, manufacturing, distribution, pricing, and execution all determine commercial outcomes. Many patented inventions never generate revenue.
A patent does not eliminate the need for regulatory approval. A patent on a pharmaceutical compound does not authorize you to sell it. You still need FDA approval (or the equivalent in other jurisdictions). The same applies to medical devices, agrochemicals, and other regulated products.
A patent does not enforce itself. The patent office does not monitor the market for infringers or file lawsuits on your behalf. Enforcement is the patent owner's responsibility and expense. Remedies -- injunctions, damages, royalties -- must be pursued through litigation or negotiation (covered in Chapter 22).
A patent does not protect an idea. A patent protects a specific technical implementation as defined by the claims. Competitors are free to achieve the same result through a different approach that falls outside your claim scope.
Frequently Asked Questions
Grant Process and Rights
Patent Term and Extensions
What's Next
This chapter covered the rights, responsibilities, and limitations that come with a granted patent. Chapter 13 introduces the Patent Cooperation Treaty (PCT) -- the international filing system that allows you to seek patent protection in over 150 countries through a single application, and the strategic decisions involved in transitioning from the international phase to national prosecution.